NASDAQ:ADROAduro BioTech Stock Price, Forecast & News

Aduro BioTech's stock was trading at $2.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ADRO stock has increased by 0.4% and is now trading at $2.37. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aduro BioTech in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Aduro BioTech.

Aduro BioTech is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Aduro BioTech.

Aduro BioTech Inc (NASDAQ:ADRO) announced its quarterly earnings data on Monday, May, 4th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.05. The biotechnology company earned $13.95 million during the quarter, compared to the consensus estimate of $8.81 million. Aduro BioTech had a negative net margin of 243.93% and a negative return on equity of 86.31%. View Aduro BioTech's earnings history.

5 analysts have issued 1-year price objectives for Aduro BioTech's shares. Their forecasts range from $4.00 to $7.00. On average, they expect Aduro BioTech's share price to reach $5.50 in the next year. This suggests a possible upside of 132.1% from the stock's current price. View analysts' price targets for Aduro BioTech.

Headlines about ADRO stock have trended somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aduro BioTech earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutAduro BioTech.

Aduro BioTech saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 2,630,000 shares, a decline of 11.1% from the April 30th total of 2,960,000 shares. Based on an average trading volume of 864,000 shares, the days-to-cover ratio is currently 3.0 days. Currently, 4.3% of the company's shares are short sold. View Aduro BioTech's Current Options Chain.

Some companies that are related to Aduro BioTech include Endo International (ENDP), Cue Biopharma (CUE), ImmunoGen (IMGN), Omeros (OMER), Arcturus Therapeutics (ARCT), Gossamer Bio (GOSS), Kura Oncology (KURA), NextCure (NXTC), Kala Pharmaceuticals (KALA), Akero Therapeutics (AKRO), Cara Therapeutics (CARA), Kadmon (KDMN), Provention Bio (PRVB), INDIVIOR PLC/S (INVVY) and Molecular Templates (MTEM). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aduro BioTech investors own include Regulus Therapeutics (RGLS), EXACT Sciences (EXAS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), Anavex Life Sciences (AVXL), PTC Therapeutics (PTCT), Amarin (AMRN) and Micron Technology (MU).

(ADRO) raised $119 million in an initial public offering on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO."

Aduro BioTech's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (6.33%), BlackRock Inc. (5.40%), Baillie Gifford & Co. (5.29%), Ikarian Capital LLC (4.50%), Lord Abbett & CO. LLC (2.09%) and JPMorgan Chase & Co. (1.85%). Company insiders that own Aduro BioTech stock include Blaine Templeman, Celeste Ferber, Elsas Andrea Van, Jennifer Lew, Natalie Sacks and Stephen T Isaacs. View institutional ownership trends for Aduro BioTech.

ADRO stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Assenagon Asset Management S.A., JPMorgan Chase & Co., Connor Clark & Lunn Investment Management Ltd., Morgan Stanley, AXA, Deutsche Bank AG, and Russell Investments Group Ltd.. Company insiders that have sold Aduro BioTech company stock in the last year include Blaine Templeman, Celeste Ferber, Elsas Andrea Van, and Stephen T Isaacs. View insider buying and selling activity for Aduro BioTech.

ADRO stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Ikarian Capital LLC, Lord Abbett & CO. LLC, Nuveen Asset Management LLC, Dupont Capital Management Corp, Thrivent Financial for Lutherans, Soleus Capital Management L.P., and Los Angeles Capital Management & Equity Research Inc.. View insider buying and selling activity for Aduro BioTech.

Shares of ADRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ADRO stock can currently be purchased for approximately $2.37.

Aduro BioTech has a market capitalization of $191.59 million and generates $17.26 million in revenue each year. The biotechnology company earns $-82,370,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Aduro BioTech employs 152 workers across the globe.

The official website for Aduro BioTech is www.aduro.com.

Aduro BioTech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-848-4400 or via email at [email protected]